Exhibit 99.1
XOMA Reports First Quarter 2024 Financial Results and Highlights Recent Activities
Earned $9 million milestone upon U.S. Food and Drug Administration’s approval of
Day One’s OJEMDA™ (tovorafenib);
XOMA is entitled to receive a mid-single digit royalty on OJEMDA™ sales
Acquired Kinnate Pharmaceuticals, adding at least $9.5 million in non-dilutive capital to XOMA’s balance sheet
Expanded the commercial royalty and milestone portfolio with the acquisitions of
economic interests in DSUVIA® (sufentanil sublingual tablet) and XACIATO™ (clindamycin phosphate)
vaginal gel 2%, as well as two Phase 3 assets
Launched XOMA’s first stock repurchase program for up to $50 million
EMERYVILLE, Calif. – May 9, 2024 (GLOBE NEWSWIRE) – XOMA Corporation (NASDAQ: XOMA), the biotech royalty aggregator, reported its first quarter 2024 financial results and highlighted recent activities.
“We continue to build the foundation for accelerating value creation with a disciplined approach to capital deployment,” stated Owen Hughes, Chief Executive Officer of XOMA. “In recent months, we’ve completed the acquisition of Kinnate, acquired economic interests in two commercial assets, as well as in two first-in-class Phase 3 assets, and initiated our first share buyback program on the heels of securing the VABYSMO® royalty-backed loan with Blue Owl. Lastly, and most importantly, the FDA approved OJEMBA™ (tovorafenib), Day One Biopharmaceuticals’ type II RAF inhibitor for patients with relapsed or refractory pLGG harboring a BRAF fusion or rearrangement or BRAF V600 mutation, ushering in an important new treatment for children living with relapsed or refractory pLGG.”
Key First Quarter Events
| Partner |
Event | |
| Talphera | XOMA added another commercial asset to its royalty portfolio with an economic interest in DSUVIA®, which is marketed by Alora Pharmaceuticals. XOMA receives 100 percent of the DSUVIA® economics until a threshold is achieved; thereafter, XOMA retains the 15 percent royalty associated with DSUVIA® commercial sales. The 75 percent royalties from Department of Defense purchases and remaining milestone payments will be shared equally between XOMA and Talphera. | |
| Kinnate Pharmaceuticals | XOMA initiated the acquisition of Kinnate Pharmaceuticals for $2.5879 in cash per share, plus a non-tradeable contingent value right (CVR) representing the right to receive 85 percent of the net proceeds from the out license or sale of Kinnate assets effected on or before April 2, 2025, and 100% of the net proceeds received from Pierre-Fabre. | |
| Zevra Therapeutics | U.S. Food and Drug Administration (FDA) accepted the arimoclomol NDA resubmission for review and set a Prescription Drug User Fee Act (PDUFA) action date of September 21, 2024. XOMA paid a $1 million milestone to LadRx based upon the achievement of this milestone. | |
| Medexus | FDA approved the pediatric label expansion application for IXINITY® [coagulation factor IX (recombinant)]. | |
| Takeda | Reported positive topline results from Phase 2 study evaluating mezagitamab (TAK-079), a potential best-in-class anti-CD38 monoclonal antibody for primary immune thrombocytopenia (ITP).i | |
| LG Chem (AVEO Oncology) | Dosed the first patient in the ficlatuzumab Phase 3 study, resulting in a $1 million milestone payment to XOMA. | |
| Compugen | Received a $1 million milestone payment from Compugen. | |
Subsequent Events
| Partner |
Event | |
| Day One Biopharmaceuticals | FDA approved Day One’s OJEMDA™ (tovorafenib) for use in pediatric patients with pediatric low-grade glioma (pLGG). XOMA earned a $9 million milestone upon the approval and is entitled to receive mid-single digit royalties from OJEMDA sales. | |
| Daré Bioscience | XOMA added economic interests to three best- or first-in-category assets to its portfolio. XACIATO™ vaginal gel 2% is commercially available and marketed by Organon. Bayer holds the U.S. rights to commercialize Ovaprene®, a hormone-free monthly intravaginal contraceptive, currently in Phase 3 clinical trials. XOMA also acquired a synthetic royalty in Sildenafil Cream, 3.6%, a Phase 3-ready asset for female sexual arousal disorder. | |
| Rezolute | Dosed first patient in its Phase 3 trial of RZ358; XOMA earned a $5.0 million milestone associated with the event. | |
Anticipated 2024 Events of Note
| Partner |
Event | |
| Zevra Therapeutics | September 21, 2024 – FDA PDUFA action date for arimoclomol NDA | |
| Takeda | In its press release dated March 13, 2024, Takeda announced plans to initiate a global Phase 3 trial of mezagitamab in ITP in fiscal year 2024.ii | |
First Quarter 2024 Financial Results
XOMA recorded total revenues of $1.5 million for the first quarter of 2024, which included a $1.0 million milestone payment received from AVEO Oncology, as compared with $0.4 million in the first quarter of 2023.
Research and development (R&D) expenses were $33,000 and $54,000, respectively, for the first quarters of 2024 and 2023. Upon closing the Kinnate merger in the second quarter of 2024, XOMA assumed operations of Kinnate’s pipeline, as well as ongoing Phase 1 study, and will incur increased R&D costs until winddown activities are complete.
General and administrative (“G&A”) expenses were $8.5 million for the first quarter of 2024, compared to $6.2 million for the first quarter of 2023. The increase of $2.3 million was primarily due to a $1.3 million increase in stock-based compensation and a $0.7 million increase in consulting and legal expenses. The increase in stock-based compensation expenses was largely due to the appointment of Mr. Hughes as our full-time Chief Executive Officer in January 2024.
In the first quarter of 2024, G&A expenses included $2.9 million in non-cash stock-based compensation expense, compared with $1.6 million in the first quarter of 2023. The increase in stock-based compensation expenses was largely due to the PSU grant associated with the appointment of Mr. Hughes as our full-time Chief Executive Officer in January 2024 combined with PSUs granted in May 2023.
Interest expense in the first quarter of 2024 was $3.6 million, representing interest related to the Blue Owl Loan established in December 2023.
The Company reported total other income, net, of $2.0 million in the first quarter of 2024, as compared to total other income, net, of $0.4 million in the corresponding period of 2023. The $1.6 million increase reflects a $1.3 million increase in investment income due to higher cash balances and higher market interest rates on our investments, as well as the change in the market price of Rezolute’s common stock.
Net loss for the first quarter of 2024 was $8.6 million, compared to a net loss of $9.8 million for the first quarter of 2023.
On March 31, 2024, XOMA had cash and cash equivalents of $142.4 million (including $6.2 million in restricted cash). On December 31, 2023, XOMA had cash and cash equivalents of $159.6 million (including $6.3 million in restricted cash). During the first quarter of 2024, XOMA received $9.8 million in cash from royalty and milestone payments and deployed $8 million to acquire new royalty and milestone economic interests. Net cash used in operating activities during the quarter was $4.9 million. On April 15, 2024, the Company paid a total of $1.4 million in cash dividends on the 8.625% Series A Cumulative Perpetual Preferred Stock (Nasdaq: XOMAP) and the 8.375% Series B Cumulative Perpetual Preferred Stock (Nasdaq: XOMAO).
About XOMA Corporation
XOMA is a biotechnology royalty aggregator playing a distinctive role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial and commercial therapeutic candidates that have been licensed to pharmaceutical or biotechnology companies. When XOMA acquires the future economics, the seller receives non-dilutive, non-recourse funding they can use to advance their internal drug candidate(s) or for general corporate purposes. The Company has an extensive and growing portfolio of assets (asset defined as the right to receive potential future economics associated with the advancement of an underlying therapeutic candidate). For more information about the Company and its portfolio, please visit www.xoma.com or follow the Company on LinkedIn.
Forward-Looking Statements/Explanatory Notes
Certain statements contained in this press release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including statements regarding the timing and amount of potential commercial payments to XOMA and other developments related to VABYSMO® (faricimab-svoa), OJEMDA™ (tovorafenib), XACIATO™ (clindamycin phosphate) vaginal gel 2%, IXINITY® [coagulation factor IX (recombinant)], DSUVIA® (sufentanil sublingual tablet), and arimoclomol; the potential occurrences of the events listed under “Anticipated 2024 Events of Note”; the anticipated timings of regulatory filings and approvals related to assets in XOMA’s portfolio; and the potential of XOMA’s portfolio of partnered programs and licensed technologies generating substantial milestone and royalty proceeds over time. In some cases, you can identify such forward-looking statements by terminology such as “anticipate,” “intend,” “believe,” “estimate,” “plan,” “seek,” “project,” “expect,” “may,” “will”, “would,” “could” or “should,” the negative of these terms or similar expressions. These forward-looking statements are not a guarantee of XOMA’s performance, and you should not place undue reliance on such statements. These statements are based on assumptions that may not prove accurate, and actual results could differ
materially from those anticipated due to certain risks inherent in the biotechnology industry, including those related to the fact that our product candidates subject to out-license agreements are still being developed, and our licensees may require substantial funds to continue development which may not be available; we do not know whether there will be, or will continue to be, a viable market for the products in which we have an ownership or royalty interest; if the therapeutic product candidates to which we have a royalty interest do not receive regulatory approval, our third-party licensees will not be able to market them; and the impact to the global economy as a result of the COVID-19 pandemic. Other potential risks to XOMA meeting these expectations are described in more detail in XOMA’s most recent filing on Form 10-Q and in other filings with the Securities and Exchange Commission. Consider such risks carefully when considering XOMA’s prospects. Any forward-looking statement in this press release represents XOMA’s beliefs and assumptions only as of the date of this press release and should not be relied upon as representing its views as of any subsequent date. XOMA disclaims any obligation to update any forward-looking statement, except as required by applicable law.
EXPLANATORY NOTE: Any references to “portfolio” in this press release refer strictly to milestone and/or royalty rights associated with a basket of drug products in development. Any references to “assets” in this press release refer strictly to milestone and/or royalty rights associated with individual drug products in development.
As of the date of this press release, the commercial assets in XOMA’s milestone and royalty portfolio are VABYSMO® (faricimab-svoa), OJEMDA™ (tovorafenib), XACIATO™ (clindamycin phosphate) vaginal gel 2%, IXINITY® [coagulation factor IX (recombinant)], and DSUVIA® (sufentanil sublingual tablet). All other assets in the milestone and royalty portfolio are investigational compounds. Efficacy and safety have not been established. There is no guarantee that any of the investigational compounds will become commercially available.
XOMA CORPORATION
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
(in thousands, except share and per share amounts)
| Three Months Ended March 31, | ||||||||
| 2024 | 2023 | |||||||
| Revenues: |
||||||||
| Revenue from contracts with customers |
$ | 1,000 | $ | — | ||||
| Revenue recognized under units-of-revenue method |
490 | 437 | ||||||
|
|
|
|
|
|||||
| Total revenues |
1,490 | 437 | ||||||
|
|
|
|
|
|||||
| Operating expenses: |
||||||||
| Research and development |
33 | 54 | ||||||
| General and administrative |
8,461 | 6,196 | ||||||
| Arbitration settlement costs |
— | 4,132 | ||||||
| Amortization of intangible assets |
— | 225 | ||||||
|
|
|
|
|
|||||
| Total operating expenses |
8,494 | 10,607 | ||||||
|
|
|
|
|
|||||
| Loss from operations |
(7,004 | ) | (10,170 | ) | ||||
| Other income (expense) |
||||||||
| Interest expense |
(3,551 | ) | — | |||||
| Other income (expense), net |
1,960 | 357 | ||||||
|
|
|
|
|
|||||
| Net loss and comprehensive loss |
$ | (8,595 | ) | $ | (9,813 | ) | ||
| Less: accumulated dividends on Series A and Series B preferred stock |
(1,368 | ) | (1,368 | ) | ||||
|
|
|
|
|
|||||
| Net loss and comprehensive loss attributable to common stockholders, basic and diluted |
$ | (9,963 | ) | $ | (11,181 | ) | ||
|
|
|
|
|
|||||
| Basic and diluted net loss per share attributable to common stockholders |
$ | (0.86 | ) | $ | (0.98 | ) | ||
|
|
|
|
|
|||||
| Weighted average shares used in computing basic and diluted net loss per share attributable to common stockholders |
11,580 | 11,460 | ||||||
|
|
|
|
|
|||||
XOMA CORPORATION
CONDENSED CONSOLIDATED BALANCE SHEETS
(in thousands, except share and per share amounts)
| March 31, | December 31, | |||||||
| 2024 | 2023 | |||||||
| (unaudited) | ||||||||
| ASSETS | ||||||||
| Current assets: |
||||||||
| Cash and cash equivalents |
$ | 136,225 | $ | 153,290 | ||||
| Short-term restricted cash |
160 | 160 | ||||||
| Short-term equity securities |
413 | 161 | ||||||
| Trade and other receivables, net |
3 | 1,004 | ||||||
| Short-term royalty and commercial payment receivables |
9,819 | 14,215 | ||||||
| Prepaid expenses and other current assets |
270 | 483 | ||||||
|
|
|
|
|
|||||
| Total current assets |
146,890 | 169,313 | ||||||
| Long-term restricted cash |
6,016 | 6,100 | ||||||
| Property and equipment, net |
40 | 25 | ||||||
| Operating lease right-of-use assets |
364 | 378 | ||||||
| Long-term royalty and commercial payment receivables |
65,577 | 57,952 | ||||||
| Other assets - long term |
533 | 533 | ||||||
|
|
|
|
|
|||||
| Total assets |
$ | 219,420 | $ | 234,301 | ||||
|
|
|
|
|
|||||
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||||||||
| Current liabilities: |
||||||||
| Accounts payable |
$ | 1,515 | $ | 653 | ||||
| Accrued and other liabilities |
1,299 | 2,768 | ||||||
| Contingent consideration under RPAs, AAAs and CPPAs |
3,000 | 7,000 | ||||||
| Operating lease liabilities |
55 | 54 | ||||||
| Unearned revenue recognized under units-of-revenue method |
2,159 | 2,113 | ||||||
| Preferred stock dividend accrual |
1,368 | 1,368 | ||||||
| Current portion of long-term debt |
6,144 | 5,543 | ||||||
|
|
|
|
|
|||||
| Total current liabilities |
15,540 | 19,499 | ||||||
| Unearned revenue recognized under units-of-revenue method – long-term |
6,692 | 7,228 | ||||||
| Long-term operating lease liabilities |
319 | 335 | ||||||
| Long-term debt |
114,528 | 118,518 | ||||||
|
|
|
|
|
|||||
| Total liabilities |
137,079 | 145,580 | ||||||
|
|
|
|
|
|||||
| Stockholders’ equity: |
||||||||
| Preferred Stock, $0.05 par value, 1,000,000 shares authorized: |
||||||||
| 8.625% Series A cumulative, perpetual preferred stock, 984,000 shares issued and outstanding at March 31, 2024 and December 31, 2023 |
49 | 49 | ||||||
| 8.375% Series B cumulative, perpetual preferred stock, 1,600 shares issued and outstanding at March 31, 2024 and December 31, 2023 |
— | — | ||||||
| Convertible preferred stock, 5,003 issued and outstanding at March 31, 2024 and December 31, 2023 |
— | — | ||||||
| Common stock, $0.0075 par value, 277,333,332 shares authorized, 11,636,355 and 11,495,492 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively |
87 | 86 | ||||||
| Additional paid-in capital |
1,314,036 | 1,311,809 | ||||||
| Accumulated deficit |
(1,231,831 | ) | (1,223,223 | ) | ||||
|
|
|
|
|
|||||
| Total stockholders’ equity |
82,341 | 88,721 | ||||||
|
|
|
|
|
|||||
| Total liabilities and stockholders’ equity |
$ | 219,420 | $ | 234,301 | ||||
|
|
|
|
|
|||||
XOMA CORPORATION
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(in thousands)
| Three Months Ended March 31, | ||||||||
| 2024 | 2023 | |||||||
| Cash flows from operating activities: |
||||||||
| Net loss |
$ | (8,595 | ) | $ | (9,813 | ) | ||
| Adjustments to reconcile net loss to net cash used in operating activities: |
||||||||
| Stock-based compensation expense |
2,856 | 1,570 | ||||||
| Common stock contribution to 401(k) |
118 | 123 | ||||||
| Amortization of intangible assets |
— | 225 | ||||||
| Depreciation |
2 | 1 | ||||||
| Accretion of long-term debt discount and debt issuance costs |
306 | — | ||||||
| Non-cash lease expense |
14 | 47 | ||||||
| Change in fair value of equity securities |
(252 | ) | 24 | |||||
| Changes in assets and liabilities: |
||||||||
| Trade and other receivables, net |
1,001 | (5 | ) | |||||
| Prepaid expenses and other assets |
213 | 269 | ||||||
| Accounts payable and accrued liabilities |
(105 | ) | 3,122 | |||||
| Operating lease liabilities |
(15 | ) | (50 | ) | ||||
| Unearned revenue recognized under units-of-revenue method |
(490 | ) | (437 | ) | ||||
|
|
|
|
|
|||||
| Net cash used in operating activities |
(4,947 | ) | (4,924 | ) | ||||
|
|
|
|
|
|||||
| Cash flows from investing activities: |
||||||||
| Payments of consideration under RPAs, AAAs and CPPAs |
(15,000 | ) | (9,600 | ) | ||||
| Receipts under RPAs, AAAs and CPPAs |
7,771 | 2,366 | ||||||
| Purchase of property and equipment |
(17 | ) | — | |||||
|
|
|
|
|
|||||
| Net cash used in investing activities |
(7,246 | ) | (7,234 | ) | ||||
|
|
|
|
|
|||||
| Cash flows from financing activities: |
||||||||
| Principal payments – debt |
(3,616 | ) | — | |||||
| Debt issuance costs and loan fees paid in connection with long-term debt |
(581 | ) | — | |||||
| Payment of preferred stock dividends |
(1,368 | ) | (1,368 | ) | ||||
| Repurchases of common stock |
(13 | ) | — | |||||
| Proceeds from exercise of options and other share-based compensation |
1,956 | — | ||||||
| Taxes paid related to net share settlement of equity awards |
(1,334 | ) | — | |||||
|
|
|
|
|
|||||
| Net cash used in financing activities |
(4,956 | ) | (1,368 | ) | ||||
|
|
|
|
|
|||||
| Net decrease in cash, cash equivalents and restricted cash |
(17,149 | ) | (13,526 | ) | ||||
| Cash, cash equivalents and restricted cash at the beginning of the period |
159,550 | 57,826 | ||||||
|
|
|
|
|
|||||
| Cash, cash equivalents and restricted cash at the end of the period |
$ | 142,401 | $ | 44,300 | ||||
|
|
|
|
|
|||||
| Supplemental Cash Flow Information: |
||||||||
| Cash paid for interest |
$ | 3,780 | $ | — | ||||
| Non-cash investing and financing activities: |
||||||||
| Accrual of contingent consideration under the Affitech CPPA |
$ | 3,000 | $ | — | ||||
| Preferred stock dividend accrual |
$ | 1,368 | $ | 1,368 | ||||
# # #
| Investor contact: | Media contact: | |
| Juliane Snowden | Kathy Vincent | |
| XOMA | KV Consulting & Management | |
| +1-646-438-9754 | +1-310-403-8951 | |
| juliane.snowden@xoma.com | kathy@kathyvincent.com |
| i |
https://www.takeda.com/newsroom/newsreleases/2024/takeda-announces-positive-topline-results-from-phase-2-study-evaluating-mezagitamab-TAK-079-a-potential-best-in-class-anti-CD38-monoclonal-antibody-for-primary-immune-thrombocytopenia/ |